Om

Taho Pharmaceuticals Ltd. is a Taiwan-based pharmaceutical company specializing in innovative drug delivery technologies, with a primary focus on transdermal patches and transmucosal oral dissolving films. Established in 2010 and headquartered in Taipei, Taho aims to enhance the clinical performance and accessibility of established pharmaceutical compounds by reengineering them into novel dosage forms that improve patient compliance, safety, and therapeutic efficacy. The company’s proprietary platforms, such as the Transepithelial Delivery System, enable the delivery of drugs through the skin or mucosal membranes, offering benefits like consistent plasma levels and reduced risk of choking—especially valuable for populations with swallowing difficulties. Taho’s development pipeline targets central nervous system, geriatric, and pediatric disorders, including products for chemotherapy-induced nausea, anticoagulation therapy, ADHD, epilepsy, and opioid addiction. Some of its products have reached major international markets, signifying its role as a bridge between innovative drug delivery and unmet medical needs in both regional and global pharmaceutical sectors.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I TAHO PHARMACEUTICALS MED ENDAVU: Køb Taho Pharmaceuticals ($6467) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Taho Pharmaceuticals, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.